Navigation Links
Indivumed Study Provides Sound Scientific Basis for a Predictive,Drug Test- Platform

HAMBURG, Germany, May 03, 2007 /PRNewswire/ -- At the April AACR Annual Meeting, Indivumed presented data which provide a sound scientific basis for a new drug test-platform to predict drug response in patients.

Tumor tissue-derived primary cell lines are currently the first choice for cancer drug testing. During their clonal selection and expansion, however, their gene and protein expression patterns change significantly, thereby losing many of their primary characteristics. Primary cell cultures are useful tools because they better reflect the molecular reality in tumors. A previous Indivumed study, however, showed that within 10 passages and after 10-12 weeks in culture, the molecular characteristics and target expression of these cells change significantly in >20% of cancer relevant genes, e.g. EGFR, HER2, VEGF, p53, CEA.

Gene expression data from short-term cultivated colorectal cancer primary cells show that in contrast to long-term cultivation (>1 month) primary cells cultivated for up to 72h do not change the molecular expression level of most cancer relevant genes. Some of the genes that play a role in cell to cell contact and tissue organization changed expression levels at various time points when compared to instantly frozen tumor tissue. These data provide a sound basis for Indivumed's new drug test-platform which allows molecular and functional analysis of molecular anti-cancer agents in a clinically meaningful system and, thus, a better prediction of clinical drug response.

Indivumed is a privately held biotech company focused on the generation, characterization and interpretation of highly standardized biological samples from human cancer. Founded in 2002 and headquartered in Hamburg, Germany with a subsidiary in Washington, D.C., Indivumed has cooperation agreements with all major oncological hospitals in the Hamburg metropolitan area. Indivumed's current tumor biobank of o
'"/>




Page: 1 2

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:12/22/2014)... Dec. 22, 2014  ConvaTec, a privately-held medical products ... been appointed Interim Chief Executive Officer of the company, ... Ken Berger .  "The Board of Directors of ... ConvaTec over the past three years," said Magnus ... "We are confident that the company is well positioned ...
(Date:12/22/2014)... STOCKHOLM , Dec. 22, 2014 /PRNewswire/ ... Auxilium Pharmaceuticals, Inc. today announced that the Committee for ... Medicines Agency (EMA) has adopted a positive opinion for ... treatment of adult men with Peyronie,s disease with a ... degrees at the start of therapy. The ...
(Date:12/22/2014)...  Mark Farrah Associates (MFA), www.markfarrah.com , ... the 2015 marketplace exchange projections and insights about ... According to a recent ASPE (Office of the ... Health and Human Services) report, an estimated 6.7 ... through the Marketplace as of October 2014 and ...
Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Insights into the Marketplace and Individual Market Growth 2
... 30 CEL-SCI Corporation,(Amex: CVM ) announced that ... Rodman & Renshaw 9th Annual Healthcare Conference being,held at ... The presentation,will be focused on its Phase III cancer ... to become a new first line standard of,care treatment ...
... Oct. 29 As a follow up to ... eliminating,Methicillin resistant Staphylococcus aureus (MRSA), the Association for,Professionals ... days next,month in Atlanta to discuss new developments ... "MRSA: The Call to Action 1 Year ...
Cached Medicine Technology:CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference 2APIC Conference to Discuss MRSA Elimination 2
(Date:12/24/2014)... 2014 Mike Billings , PT, ... Derek Fenwick, PT, MBA, GCS, Director of Professional ... from the passing of the Improving Medicare Post-Acute ... this taping of the Infinicast, the two leaders discuss ... Social Security Act to standardize post-acute assessment data for ...
(Date:12/24/2014)... (HealthDay News) -- A new, injectable weight-loss drug has ... The agency on Tuesday approved Saxenda (liraglutide) for ... overweight and have at least one weight-related health condition, ... high cholesterol. Patients taking the drug, made by ... exercise regularly, the FDA noted. "Obesity is a ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 (HealthDay ... call for giving the cholesterol-lowering drugs known as statins to ... These new standards bring the association in line with the ... recommend giving low- or high-dose statins to all people at ... agree that the decision to start a statin should be ...
(Date:12/24/2014)... The 2014 Market Research Report on ... research report on COC industry. For an overview ... its definition, classification, application, industry chain structure, industry ... also presents product specification, manufacturing process, and product ... technology and applications. Analysis also covers upstream raw ...
(Date:12/24/2014)... December 24, 2014 Dental implants benefit ... a tooth replacement. They offer the strongest and most ... over other forms of tooth replacement. They will never ... the adjacent teeth for support, and they prevent the ... been told that they are not suitable candidates for ...
Breaking Medicine News(10 mins):Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 3Health News:Innovative Dental Implant Procedure to Gain Momentum in the New Year 2
... Elsevier Middle East announces that the Journal ... been selected for inclusion in MEDLINE, the premier bibliographic database ... articles indexed, the indexing terms and the abstract printed in ... Indexing using the US National Library of Medicine,s (NLM) advanced ...
... A new independent study by HealthGrades of patient outcomes ... had a 72% lower risk of dying when compared with ... held steady over the past years even as overall mortality ... performed at the level of 5-star rated hospitals over the ...
... release is available in French . ... anesthesia has been performed at the McGill University Health ... work from remote locations, was put to work this ... providing automated anesthesia since 2008. The two combined to ...
... By Steven Reinberg HealthDay Reporter , TUESDAY, ... a benefit to mothers and their infants from taking supplemental ... new Australian study finds no such benefit. In ... women, the researchers found no benefit from DHA in reducing ...
... Reporter , TUESDAY, Oct. 19 (HealthDay News) -- Patients ... attacks, stroke and other problems after their operations, and ... studies find. In the aspirin study, researchers identified ... surgeries. Of those, 860 were taking aspirin in the ...
... 2010 Dogs may not only be man,s best friend, ... of children with special needs. According to a new Universit ... the anxiety and enhance the socialization skills of children with ... Psychoneuroendocrinology may be a relatively simple solution to ...
Cached Medicine News:Health News:New ratings of American hospitals released with quality study by HealthGrades 2Health News:New ratings of American hospitals released with quality study by HealthGrades 3Health News:McSleepy meets DaVinci 2Health News:Fish Oil Pills Don't Affect Postpartum Depression: Study 2Health News:Fish Oil Pills Don't Affect Postpartum Depression: Study 3Health News:Fish Oil Pills Don't Affect Postpartum Depression: Study 4Health News:Aspirin, Statins May Reduce Problems After Heart Surgery 2Health News:Aspirin, Statins May Reduce Problems After Heart Surgery 3Health News:Children's best friend 2
Pneumatic oscillating saw, 35k cpm, available with various hose connector styles....
... hand throttle. Accepts all 1000 and 2000 ... hose 9000-000, or existing hose with Microaire ... or existing hose with Linvatec/Hall connector (1000-200). ... hose with 3M connector (1000-300). , 10ft ...
Pneumatic extended oscillating saw, 35k cpm, available with various hose connector styles....
Pneumatic pencil-grip wire driver, 3000 rpm, available with various hose connector styles....
Medicine Products: